Patents by Inventor Sylvie ASSADOURIAN

Sylvie ASSADOURIAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ARTICLE OF MANUFACTURE COMPRISING AFLIBERCEPT OR ZIV-AFLIBERCEPT
    Publication number: 20180078496
    Abstract: Article of manufacture comprising a packaging material, a polypeptide of SEQ ID NO:1, aflibercept or ziv-aflibercept or a biosimilar thereof, and a label comprising a printed statement which informs a prospective user of adverse events or adverse reactions.
    Type: Application
    Filed: January 18, 2017
    Publication date: March 22, 2018
    Inventors: Sylvie ASSADOURIAN, Remi CASTAN, Emmanuelle MAGHERINI
  • Use of Anti-MUC1 Maytansinoid Immunoconjugate Antibody for the Treatment of Solid Tumors
    Publication number: 20160347856
    Abstract: The present invention concerns a conjugate comprising (i) a cell binding agent which binds to the human mucin-1 (MUC1) glycoprotein, linked to (ii) at least one cytotoxic agent, for use to treat cancer, wherein said conjugate is administered at a dose of at least 120 mg/m2.
    Type: Application
    Filed: July 30, 2014
    Publication date: December 1, 2016
    Inventors: Sylvie Assadourian, Dominique Mignard
  • ARTICLE OF MANUFACTURE COMPRISING AFLIBERCEPT OR ZIV-AFLIBERCEPT
    Publication number: 20150216795
    Abstract: Article of manufacture comprising a packaging material, a polypeptide of SEQ ID NO:1, aflibercept or ziv-aflibercept or a biosimilar thereof, and a label comprising a printed statement which informs a prospective user of adverse events or adverse reactions.
    Type: Application
    Filed: February 2, 2015
    Publication date: August 6, 2015
    Inventors: Sylvie ASSADOURIAN, Rémi CASTAN, Emmanuelle MAGHERINI
  • ANTI-TUMORAL COMPOSITION COMPRISING THE COMPOUND 1-(6--1,3-BENZOTHIAZOL-2-YL)-3-(2-MORPHOLIN-4-YLETHYL)UREA
    Publication number: 20150119391
    Abstract: The present invention concerns an anti-tumoral composition comprising the compound 1-(6-{[6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}1,3-benzothiazol-2-yl)-3-(2-morpholin-4-ylethyl)urea and its use in the treatment of cancer.
    Type: Application
    Filed: January 9, 2015
    Publication date: April 30, 2015
    Inventors: Jean-Rene AUTHELIN, Tsiala BENARD, Amandine MATHIEU, Maria-Teresa PERACCHIA, Helene GOULAOUIC, Sylvie ASSADOURIAN